Axsome Therapeutics Inc is a New York-based biopharmaceutical company focused on developing innovative treatments for central nervous system disorders. Its product lineup includes Auvelity for major depressive disorder and Sunosi for narcolepsy or obstructive sleep apnea-related daytime sleepiness. The company is also advancing several drugs through clinical trials, targeting conditions like Alzheimer's disease agitation, migraine, narcolepsy, fibromyalgia, and more. Axsome's commitment to addressing unmet medical needs in mental health and neurological conditions underscores its research-driven approach.
Axsome reports at 7:00 AM ET, confirmed, and the whole $10.9 billion valuation rides on Auvelity and Sunosi prescription growth holding pace with consensus. Guidance commentary here also sets the tone for the rest of the CNS group.
Oversold shares of Nike (NYSE: NKE | NKE Price Prediction) are on the run. All on news that CEO Elliott Hill bought 16,400 shares for about $1 million. This follows news that…
